As of Friday close, Beam Therapeutics Inc.’s (NASDAQ:BEAM) stock was down -$0.15, moving down -0.64 percent to $23.34. The average number of shares traded per day over the past five days has been 936,960 shares. 1 time new highs have been achieved over the past 5 days, with a -$2.21 fall in that time frame. In the last twenty days, the average volume was 920,675, while in the previous 50 days, it was 874,314.
Since last month, BEAM stock retreated -24.66%. Shares of the company fell to $22.84 on 08/17/23, the lowest level in the past month. A 52-week high of $62.31 was reached on 02/02/23 after having rallying from a 52-week low of $22.84. Since the beginning of this year, BEAM’s stock price has dropped by -40.32% or -$15.77, and marked a new high 9 times. However, the stock has declined by -62.54% since its 52-week high.
BEAM stock investors should be aware that Beam Therapeutics Inc. (BEAM) stock had its last reported insider trading activity 26 days ago on Jul 24. Ciaramella Giuseppe, the President and CSO of the company, disposed of 1,206 shares for $32.01 on Jul 24. It resulted in a $38,604 divestment by the insider. Ciaramella Giuseppe sold 155,324 shares at an average price of $32.06 on Jul 21. The insider now owns 48,250 shares following the transaction. On Jul 10, Chief Medical Officer Simon Amy sold 391 shares at $30.48 apiece. The transaction was valued at $11,918.
Valuation Metrics
The stock’s beta is 1.64. Besides these, the trailing price-to-sales (P/S) ratio of 22.05, the price-to-book (PB) ratio of 2.20.
The latest dividend of $0.2250 per share was paid out, remained unchanged from last year’s $0.2250.
Financial Health
In the three months ended June 29, Beam Therapeutics Inc.’s quick ratio stood at 5.20, while its current ratio was 5.20, showing that the company is able to pay off its debt. Based on annual data, BEAM earned $399.4 million in gross profit and brought in $60.92 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -46.40%. Return on equity (ROE) for the past 12 months was -43.30%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. BEAM’s revenue rose 17.25% to $24.21 million during the quarter, while net income inched up to $20.12 million. While analysts expected Beam Therapeutics Inc. to report -$1.42 quarterly earnings, the actual figure was -$1.08 per share, beating the consensus estimate by 23.90%. During the quarter, the company generated -$104.91 million in EBITDA. The liabilities of Beam Therapeutics Inc. were 542.24 million at the end of its most recent quarter ended June 29, and its total debt was $177.13 million. The value of shareholders’ equity is $79.2 million.
Technical Picture
This quick technical analysis looks at Beam Therapeutics Inc.’s (BEAM) price momentum. With a historical volatility rate of 34.52%, the RSI 9-day stood at 21.75% on 18 August.
With respect to its five-day moving average, the current Beam Therapeutics Inc. price is down by -8.65% percent or -$2.21. At present, BEAM shares trade -27.22% below its 20-day simple moving average and -23.58% percent below its 100-day simple moving average. However, the stock is currently trading approximately -32.07% below its SMA50 and -47.03% below its SMA200.
Stochastic coefficient K was 4.55% and Stochastic coefficient D was 4.03%, while ATR was 1.24. Given the Stochastic reading of 6.46% for the 14-day period, the RSI (14) reading has been calculated as 25.83%. As of today, the MACD Oscillator reading stands at -1.41, while the 14-day reading stands at -2.33.
Analyst Ratings
Bernstein launched its rating on Beam Therapeutics Inc. (NASDAQ: BEAM) to a Mkt perform in a note to investors on March 21, 2023. Beam Therapeutics Inc. (BEAM) has been rated Overweight by analysts. According to 0 brokerage firms, BEAM is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Beam Therapeutics Inc. stock as buy, with 11 recommending it as overweight.
With a median target price of $56.00, the current consensus forecast for the stock is $32.00 – $105.00. Based on these forecasts, analysts predict Beam Therapeutics Inc. (BEAM) will achieve an average price target of $63.40.
